Travere Therapeutics的FILSPARI®补充新药申请获FDA受理,用于FSGS治疗Travere Therapeutics FILSPARI® sNDA Accepted by FDA for FSGS Treatment

动脉网
16 May

Travere Therapeutics, Inc. has announced that the US Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for FILSPARI® (sparsentan) for the treatment of focal ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10